Scancell Holdings Plc DNA ImmunoBody Patent Granted in Europe
June 26 2017 - 2:00AM
RNS Non-Regulatory
TIDMSCLP
Scancell Holdings Plc
26 June 2017
26 June 2017
Scancell Holdings Plc
("Scancell" or the "Company")
DNA ImmunoBody(R) Patent Granted in Europe
Scancell Holdings plc, ('Scancell' or the 'Company') the
developer of novel immunotherapies for the treatment of cancer, is
pleased to announce that a patent for its DNA ImmunoBody(R)
technology has now been granted in Europe.
The European patent, number 2134357, granted by the European
Patent Office, covers Scancell's DNA ImmunoBody(R) platform
technology and is key to the protection of the Company's pipeline
of ImmunoBody(R) vaccines, including lead candidates, SCIB1 and
SCIB2.
On issuance, this patent will extend coverage of Scancell's
intellectual property into another important market for Scancell.
Counterparts to this patent have already been granted in the United
States, Australia and Japan.
The European patent covers the following countries: Austria,
Belgium, Switzerland, Germany, Denmark, Spain, Finland, France,
United Kingdom, Ireland, Italy, Netherlands, Norway, Poland,
Portugal, Sweden and Turkey.
Dr. Richard Goodfellow, Chief Executive Officer of Scancell,
commented:
"The addition of this key European patent for DNA ImmunoBody(R)
significantly bolsters our global intellectual property portfolio
as we position the company for future growth."
For Further Information:
Dr John Chiplin, Executive
Chairman +1 858 900 2646
Dr Richard Goodfellow, Scancell Holdings +44 (0) 20 3727
CEO Plc 1000
Freddy Crossley (Corporate +44 (0) 20 7886
Finance) 2500
Tom Salvesen (Corporate Panmure Gordon +44 (0) 20 7886
Broking) & Co 2500
+44 (0) 20 3727
Mo Noonan/Simon Conway FTI Consulting 1000
About Scancell
Scancell is developing novel immunotherapies for the treatment
of cancer based on its ImmunoBody(R) and Moditope(R) technology
platforms.
Scancell's first ImmunoBody(R), SCIB1 is being developed for the
treatment of melanoma. Data from the Phase 1/2 clinical trial
demonstrate that SCIB1, when used as monotherapy, has a marked
effect on tumour load, produces a melanoma-specific immune response
and highly encouraging survival trend without serious side effects.
In patients with resected disease there is increasing evidence to
suggest that SCIB1 may delay or prevent disease recurrence.
Scancell's ImmunoBody(R) vaccines target dendritic cells and
stimulate both parts of the cellular immune system: the helper cell
system where inflammation is stimulated at the tumour site and the
cytotoxic T-lymphocyte or CTL response where immune system cells
are primed to recognise and kill specific cells.
Pre-clinical data on a combination of SCIB1 or SCIB2 and
checkpoint inhibition (blockade of the PD-1 or CTLA-4 immune
checkpoint pathways) have shown enhanced tumour destruction and
significantly longer survival times than when either treatment was
used alone. Experimental data suggests that the high avidity T
cells induced by ImmunoBody(R) vaccines increase expression of
PDL-1 on the tumour cell surface, thereby making the tumours more
sensitive to checkpoint inhibitor drugs. Re-challenging animals
with tumour cells after SCIB1 treatment resulted in 100% survival
suggesting that ImmunoBody(R) induces a powerful memory response.
Such an effect has not been observed with checkpoint
inhibitors.
Scancell has also identified and patented a series of modified
epitopes that stimulate the production of killer CD4+ T cells that
destroy tumours without toxicity. The Directors believe that the
Moditope(R) platform could play a major role in the development of
safe and effective cancer immunotherapies in the future.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAOKPDKCBKDKAB
(END) Dow Jones Newswires
June 26, 2017 02:00 ET (06:00 GMT)
Scancell (LSE:SCLP)
Historical Stock Chart
From Apr 2024 to May 2024
Scancell (LSE:SCLP)
Historical Stock Chart
From May 2023 to May 2024